The transition from preclinical development to clinical trials is a critical, with approximately 89% of drugs failing. Nearly half of these failures stem from unexpected and unmanageable human ...

US FDA to Phase ... development of monoclonal antibody therapies and other drugs with "human-relevant methods," including the use of AI-based models. The new approach would help improve drug ...